Evidence-based Clinical Care: Pulmonary Embolism Clinical Pathway
This course provides practitioners with evidence-based practices related to the risk stratification of pulmonary embolism. This includes practices that promote early suspicion, appropriate diagnostic work-up and consensus treatment algorithms specific to the levels of risk, as well as the recognition of the added value of implementing a Pulmonary Embolism (PERT) Team in the process.
Note to Physicians: Be sure to bookmark this course to access all protocols, pathways, policies and procedures at your convenience via your CME Portal account. All power plans are available in Cerner. All EBCC deliverables will be available on the EBCC website.
Cardiothoracic Surgeons, Cardiologists, Critical Care Physicians, Pulmonologists, Emergency Department Physicians, Interventional and Diagnostic Radiologists, Vascular Medicine Specialists, Advanced Practice Providers, Nurses, Nurse Practitioners, Echocardiology Technicians and Hospitalists.
- Explain the necessity of system standardization of treatment options for the pulmonary embolism (PE) patient based on current evidence-based practices.
- Distinguish severity levels of PE, including massive, sub-massive and low-risk PE, the corresponding clinical pathways and associated power plans, based on evidence-based practices in the acute care setting.
- Stratify PE patients based on pulmonary thromboembolism (PTE) risk assessment.
- Identify a PE utilizing standardized echocardiogram and imaging criteria and implement appropriate treatment.
- Monitor quality measures associated with the treatment of PE patients.
- Recognize the role of the Pulmonary Embolism Response Team (PERT) and Rapid Response Team (RRT) in the diagnosis and treatment of PE.
Javier Perez-Fernandez, M.D.
Director of Pulmonary Services at West Kendall Baptist Hospital
Director of Critical Care Services at Baptist Hospital
Associate Clinical Professor at Florida International University
Javier Perez-Fernandez, M.D., has indicated that he is on the speakers bureau with Boehringer Ingelheim, Sunovion and Astra-Zeneca. Dr. Perez-Fernandez will not include off-label or unapproved product usage in his presentation or discussion.
James Benenati, M.D., has indicated that he is a stockholder with Penumbra and a consultant with Bard Medical and Penumbra.
Ripal Gandhi, M.D., has indicated that he is a consultant with Bard, BTG, Sirtex, Medtronic and Boston SCI.
Adam Geronemus, M.D., has indicated that he is on the speakers bureau with Gore, Bard and Merit.
F. Javier Jimenez-Carcamo, M.D., has inidcated that he is on the speakers bureau with Bayer, Actelion and United Therapeutics and on the advisory board with Actelion and United Therapeutics.
Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose.
Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
Baptist Health South Florida designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 General certificate of attendance
- 1.00 Nurse Practitioners
- 1.00 Florida Board of Nursing
This site is supported on the most recent stable releases of the following browsers:
This site is supported on the following mobile devices:
If you are experiencing technical difficulties or have received an error message, please send an email to CME@baptisthealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours.